|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM319462064 |
| 003 |
DE-627 |
| 005 |
20240229152505.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202002094
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1306.xml
|
| 035 |
|
|
|a (DE-627)NLM319462064
|
| 035 |
|
|
|a (NLM)33382144
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Wang, Yue
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Self-Amplifying Nanotherapeutic Drugs Homing to Tumors in a Manner of Chain Reaction
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 14.10.2021
|
| 500 |
|
|
|a Date Revised 26.02.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2020 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Active tumor-targeting drug delivery has great potency in cancer therapy. However, the targeting efficiency of traditional active tumor-targeting nanotherapeutic drugs is limited by the scarcity of their accessible targets/receptors in tumors. Here, a novel self-amplifying tumor-targeting strategy with a chain reaction mechanism is developed. A coagulation targeting peptide (GNQEQVSPLTLLKXC, termed A15)-decorated poly(L-glutamic acid)-graft-maleimide poly(ethylene glycol)/combretastatin A4 conjugate (A15-PLG-CA4) is prepared to obtain a self-amplifying nanotherapeutic platform homing to tumors. After administration to tumor-bearing mice, A15-PLG-CA4 starts a chain reaction cycle consisting of intratumoral hemorrhage, target FXIIIa amplification, blood clot binding, and CA4 release in tumors. In this way, A15-PLG-CA4 increases the level of its accessible targets (FXIIIa) in a manner of chain reaction. The FXIIIa activity at 8 h is 4.1-fold more than the one at 0 h in the C26 tumors treated with A15-PLG-CA4. The total CA4 concentration at 24 h is 2.9-fold more than the control. A15-PLG-CA4 shows a significantly higher antitumor effect against large C26 tumors (≈500 mm3 ) thanks to the remarkable tumor-targeting ability compared with the control. Therefore, this report highlights the potential of the self-amplifying tumor-targeting strategy in the development of next generation active tumor-targeting nanotherapeutic drugs for tumor therapy
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a chain reactions
|
| 650 |
|
4 |
|a glutamic acid
|
| 650 |
|
4 |
|a nanomedicine
|
| 650 |
|
4 |
|a tumor-targeting
|
| 650 |
|
4 |
|a vascular disrupting agents
|
| 650 |
|
7 |
|a Antineoplastic Agents, Phytogenic
|2 NLM
|
| 650 |
|
7 |
|a Biomarkers, Tumor
|2 NLM
|
| 650 |
|
7 |
|a Nanocapsules
|2 NLM
|
| 650 |
|
7 |
|a Peptides
|2 NLM
|
| 650 |
|
7 |
|a Stilbenes
|2 NLM
|
| 650 |
|
7 |
|a Polyglutamic Acid
|2 NLM
|
| 650 |
|
7 |
|a 25513-46-6
|2 NLM
|
| 650 |
|
7 |
|a Polyethylene Glycols
|2 NLM
|
| 650 |
|
7 |
|a 3WJQ0SDW1A
|2 NLM
|
| 650 |
|
7 |
|a Factor XIIIa
|2 NLM
|
| 650 |
|
7 |
|a EC 2.3.2.13
|2 NLM
|
| 650 |
|
7 |
|a fosbretabulin
|2 NLM
|
| 650 |
|
7 |
|a I5590ES2QZ
|2 NLM
|
| 700 |
1 |
|
|a Shen, Na
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Ying
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Yu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tang, Zhaohui
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Xuesi
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 33(2021), 7 vom: 01. Feb., Seite e2002094
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:33
|g year:2021
|g number:7
|g day:01
|g month:02
|g pages:e2002094
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202002094
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 33
|j 2021
|e 7
|b 01
|c 02
|h e2002094
|